Lv6
2000 积分 2021-12-16 加入
感谢科研通大公无私。
Neoadjuvant Chemoimmunotherapy in Resectable NSCLC With PD-L1 Expression < 1%: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
10小时前
已完结
Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort
12小时前
已完结
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study
3天前
已完结
Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges
14天前
已完结
Survival of Squamous Cell Carcinoma Versus Adenocarcinoma in Resected Stage I-III Non-small Cell Lung Cancer
15天前
已完结
ASO Author Reflections: Is Histology More Than a Covariate? Revisiting Squamous Cell Carcinoma and Adenocarcinoma in Resected Non-small Cell Lung Cancer
15天前
已完结
P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR –Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape
20天前
已完结
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study
25天前
已完结
Antibody–Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond
28天前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
28天前
已完结
皖公网安备34019202002308
